Standard
Caristo wins FDA authorization for cardiovascular risk predictor
In a significant advancement for preventative cardiology, Caristo Diagnostics, a biotechnology firm born out of research at the University of Oxford, is preparing for the imminent commercial launch of its artificial intelligence-driven cardiac imaging platform in the United States. The technology, known as CaRi-Heart, is designed to identify high-risk patients who might otherwise be overlooked…
